We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Key Proteins in Urine Samples Detect Preeclampsia

By LabMedica International staff writers
Posted on 15 Dec 2010
Print article
Protein biomarkers in the urine of women in the early stage of pregnancy can determine whether they will develop preeclampsia.

A simple measurement of key proteins in spot urine samples and changes in the urinary protein profile early in pregnancy might predict the development of preeclampsia, which typically does not appear until later in pregnancy.

Preeclampsia is a condition in pregnancy characterized by abrupt hypertension (a sharp rise in blood pressure), albuminuria (leakage of large amounts of the protein albumin into the urine) and edema (swelling) of the hands, feet, and face. Preeclampsia is the most common complication of pregnancy.

Scientists from the Leicester General Hospital, (Leicester, UK), analyzed urine samples obtained before 20 weeks of gestation from 145 pregnant women who either did or did not develop preeclampsia. The prospective longitudinal study involved pregnant women from a high-risk obstetric outpatient clinic. Urine samples were taken and analyzed the same day with surface enhanced laser desorption/ionization time-of-flight mass spectrometry.

After delivery, patients were categorized as having had preeclampsia or a normal pregnancy. A spectral analysis of the urine samples of preeclampsia and nonpreeclampsia pregnancies taken before 20 weeks of gestation was performed with an artificial neural network algorithm and multivariate nonlinear regression. A random sampling of 50 test datasets validated the model. The results identified a panel of five protein peaks that predicted preeclampsia with 92% accuracy; the test datasets showed a sensitivity of 87% and a specificity of 82%.

Matt Hall, MBChB, of the University of Leicester (Leicester, UK), and the lead author of the study, said, "Given that proteinuria is a key diagnostic and prognostic factor in preeclampsia, the renal morphological changes occur early in the disease, and the initiation of this process begins four to five months before the clinical manifestations."

Arlene Chapman, MD, professor of medicine at Emory School of Medicine (Atlanta, GA, USA), said, "Numerous biomarkers have been investigated to try to detect the condition early, most notably soluble FMS-like tyrosine kinase and soluble endoglin, peptides that are produced by the placenta. The identification of a urinary proteomic fingerprint could help with the diagnosis.” The study was presented on November 19, 2010, at the Annual Meeting of the American Society of Nephrology held in Denver (CO, USA).

Related Links:
Leicester General Hospital
Emory School of Medicine
University of Leicester


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.